Matthew Link Sells 5,042 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Matthew Link sold 5,042 shares of the company’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $2.31, for a total value of $11,647.02. Following the completion of the transaction, the insider now owns 830,551 shares of the company’s stock, valued at $1,918,572.81. The trade was a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Sight Sciences Stock Performance

Shares of Sight Sciences stock opened at $2.30 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. Sight Sciences, Inc. has a 1 year low of $2.04 and a 1 year high of $8.45. The firm’s 50-day simple moving average is $2.67 and its 200-day simple moving average is $3.86. The firm has a market cap of $118.07 million, a PE ratio of -2.25 and a beta of 2.52.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The firm had revenue of $19.07 million for the quarter, compared to analyst estimates of $18.98 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. During the same quarter in the previous year, the company earned ($0.22) EPS. Equities analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on SGHT shares. UBS Group dropped their target price on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research report on Monday, January 27th. Piper Sandler decreased their target price on Sight Sciences from $5.50 to $3.50 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a report on Thursday, March 6th. Citigroup decreased their price target on Sight Sciences from $4.60 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Stifel Nicolaus dropped their price target on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.83.

Institutional Trading of Sight Sciences

Several institutional investors have recently added to or reduced their stakes in SGHT. KCK LTD. acquired a new position in shares of Sight Sciences in the 4th quarter valued at about $15,925,000. Barclays PLC grew its position in Sight Sciences by 317.4% in the 3rd quarter. Barclays PLC now owns 50,300 shares of the company’s stock valued at $317,000 after buying an additional 38,248 shares in the last quarter. Geode Capital Management LLC increased its stake in Sight Sciences by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock valued at $4,941,000 after buying an additional 12,709 shares during the period. State Street Corp increased its position in shares of Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after purchasing an additional 95,843 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Sight Sciences by 46.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock worth $1,310,000 after buying an additional 65,767 shares in the last quarter. Institutional investors own 55.51% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.